|
|
|
Company
Name |
Short
Summary |
| Achaogen |
Achaogen is focused on the research and development of antibiotics for the treatment of serious multi-drug resistant (MDR) Gram-negative bacterial infections. |
| BiPar Sciences |
BiPar Sciences is focused on the development of PARP inhibitors to treat multiple cancer types. |
| Catalyst Biosciences |
Catalyst Biosciences is focused on creating novel catalytic biopharmaceutical products based on engineered human proteases. |
| Cato
Research |
Cato Research is a global is
a full-service contract research and development
organization (CRO). |
| Celera |
Celera is a healthcare business that uses knowledge of human variability to provide new tests and services to personalize disease management.
|
| Cell
Genesys |
Cell
Genesys is focused on the development and commercialization
of gene therapies to treat major life-threatening
diseases, including cancer and cardiovascular
disease. |
| CoMentis |
CoMentis is focused on the development of two technology platforms: (i) aspartic protease inhibitors and (ii) nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated or cognitive disorders. |
| Cytokinetics |
Cytokinetics
is focused on the complementary missions of drug
discovery and the commercialization of novel cellular
bioinformatics technologies. |
| CytomX |
CytomX is focused on the research and development of monclonal antibody therapeutics. |
| DiaDexus |
DiaDexus
is a company formed as a joint venture between
SmithKline Beecham Corp. and Incyte Pharmaceuticals,
Inc., dedicated to the discovery and commercialization
of novel molecular diagnostics. |
| Exelixis |
Exelixis
is a rapidly growing, well-funded, privately held
biopharmaceutical company whose mission is to
identify novel therapeutic targets for drug discovery
by elucidating the biochemical pathways involved
in human diseases. |
| FibroGen |
FibroGen
is a biotechnology company focusing on the development
of innovative recombinant human/animal collagen
biomaterials and novel anti-fibrotic pharmaceuticals. |
| Five Prime Therapeutics |
Five Prime Therapeutics is focused on the discovery, research, and development of protein and antibody drugs. |
| Fluidigm |
Fluidigm develops and distributes systems based on integrated fluidic circuits (IFCs). |
| Genentech |
Genentech,
Inc. is a leading biotechnology company using
human genetic information to develop, manufacture
and market biopharmaceuticals that address significant
unmet medical needs. |
| Hana Biosciences |
Hana Biosciences is focused on the acquisition, research, development, and commercialization of products for the treatment cancer and related conditions. |
| Hermes Biosciences |
Hermes Biosciences is focused on the development of molecularly targeted nanocarrier systems for therapeutic and other medical applications. |
| KAI Pharmaceuticals |
KAI Pharmaceuticals is focused on the development of products in the areas of cardiovascular, renal, and pain. |
| KaloBios Pharmaceuticals |
KaloBios is focused on the development of antibody therapeutics in autoimmunity, infectious disease, and cancer. |
| MacroGenics |
MacroGenics is focused on the develompent and commercialization of biologics for the treatment of autoimmune disorders, cancer and infectious diseases. |
| Monogram Biosciences |
Monogram Biosciences is focused on the research, development, and commercialization of molecular diagnostics for infectious diseases, cancer and other serious diseases. |
| NGM Biopharmaceuticals |
NGM Biopharmaceuticals is focused on the development of treatments for metabolic diseases, such as obesity, muscle wasting and cardiovascular disease in addition to diabetes. |
| Nodality |
Nodality is focused on utilizing advanced quantitative flow cytometry to enable clinical decision making for cancer treatment. |
| Onyx Pharmaceuticals |
Onyx Pharmaceuticals is focused on the research, development and commercialization of therapeutics for the treatment of cancer. |
| OXiGENE |
OXiGENE is focused on the discovery and development of therapeutics for patients with cancer and sight-threatening eye diseases and conditions. |
| Pfizer |
Pfizer Inc. is involved in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide. |
| Poniard Pharmaceuticals |
Poniard Pharmaceuticals is focused on the development and commercialization of small molecule products for the treatment of cancer. |
| Portola Pharmaceuticals |
Portola Pharmaceuticals is focused on developing therapeutics for the treatment of cardiovascular disease and inflammation. |
| Rigel |
Rigel
employs a set of unique technologies in the rapid
discovery and validation of novel pharmaceutical
targets, as well as in the design of therapeutic
agents which regulate the function of these targets
in specific disease processes. |
| Sunesis
Pharmaceuticals |
Sunesis
Pharmaceuticals is committed to becoming a leader
in the discovery of important new pharmaceutical
products for the treatment of human disease. They
are doing this by applying a revolutionary new
approach to drug discovery that is based on a
novel chemical methodology combined with critical
insights into the nature of molecular recognition
between natural macromolecules and their substrates
or ligands. |
| Sutro Biopharma |
Sutro Biopharma is focused on application of an Open Cell Free Synthesis (OCFS) technology which is an optimized E. coli extract for protein production. |
| Theravance |
Theravance is focused on small molecule drugs across a number of therapeutic areas with an initial focus on respiratory disease, bacterial infections and gastrointestinal disorders. |
| Titan
Pharmaceuticals |
Titan
Pharmaceuticals develops products for the treatment
of cancer and central nervous system disorders. |
| Trellis Bioscience |
Trellis Bioscience is focused on monoclonal antibody therapeutics for infectious disease and oncology. |
